Table 1.
Patient characteristics, lung function measures, and peripheral blood counts
| Characteristic | HIV+ low DLCO (n = 10) | HIV+ preserved DLCO (n = 9) | HIV− low DLCO (n = 11) | HIV− preserved DLCO (n = 9) | P‐valuea |
|---|---|---|---|---|---|
| Age, years | 52 (51–57) | 49 (40–53) | 50 (48–57) | 48 (46–50) | 0.03 |
| Black race | 90% | 67% | 91% | 56% | 0.3 |
| Smoking pack‐years | 35 (21–40) | 28 (10–34) | 20 (16–26) | 12 (8–31) | 0.2 |
| CD4 cell count, cells/mm3 | 310 (241–323) | 507 (441–707) | – | – | 0.004 |
| HIV RNA copies/mLb | <50 | <50 | – | – | 0.5 |
| On ART | 70% | 100% | – | – | 0.2 |
| Pulmonary function tests | |||||
| FEV1, % predicted | 79 (72–88) | 109 (105–110) | 79 (70–92) | 96 (89–103) | 0.002 |
| FVC, % predicted | 99 (95–103) | 85 (77–95) | 105 (102–115) | 81 (74–87) | 0.0008 |
| FEV1/FVC, % | 75 (70–81) | 79 (75–82) | 80 (76–82) | 75 (71–80) | 0.3 |
| DLCO, % predicted | 39 (37–40) | 83 (71–84) | 40 (35–43) | 74 (67–89) | 0.0001 |
| Chest CT scan data | |||||
| Any radiographic emphysema | 89% | 56% | 70% | 33% | 0.09 |
| Pulmonary artery enlargement | 22% | 56% | 10% | 11% | 0.1 |
| WBC count, cells x 109 per liter | 4.9 (3.9–5.9) | 5.9 (3.7–6.2) | 7.1 (5.4–8.7) | 6.9 (6.5–10) | 0.01 |
| Neutrophils | 52% (41–58%) | 49% (31–55%) | 56% (43–64%) | 55% (50–65%) | 0.5 |
| Lymphocytes | 33% (25–46%) | 37% (34–53%) | 31% (27–41%) | 33% (27–41%) | 0.6 |
| Monocytes | 12% (9–14%) | 8% (7–10%) | 8% (6–11%) | 7% (6–7%) | 0.02 |
ART, antiretroviral therapy; CT, computed tomography; FVC, forced vital capacity. Continuous variables are presented as median values with interquartile ranges (IQR).
a
P‐value is for comparison across all four groups of subjects, except for HIV‐related variables, which only compare HIV+ subjects with low versus preserved DLCO.
b
Limit of detection for HIV RNA is 50 copies/mL.